Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclophosphamide pneumonitis.

G J Mark, A Lehimgar-Zadeh, B D Ragsdale

    Thorax
    |February 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Cyclophosphamide, a chemotherapy drug, can rarely cause lung damage like interstitial pneumonitis and fibrosis. This case highlights the risk in patients treated for glomerulonephritis, not just lymphoma.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    From a dry bone to a genetic portrait: a case study of sickle cell anemia.

    American journal of physical anthropology·2000
    Same author

    Occupational risk factors for sarcoma subtypes.

    Epidemiology (Cambridge, Mass.)·1999
    Same author

    Occupational chlorophenol exposure and soft tissue sarcoma risk among men aged 30-60 years.

    American journal of epidemiology·1998
    Same author

    Juvenile active ossifying fibroma. Report of four cases.

    Journal of neurosurgery·1997
    Same author

    Mucormycosis in a patient with acquired immunodeficiency syndrome.

    Archives of dermatology·1997
    Same author

    The irrelevance of contemporary orthopedic pathology to specimens from antiquity.

    Paleopathology newsletter·1996
    Same journal

    Mediastinal amyloidosis mimicking advanced lung cancer.

    Thorax·2026
    Same journal

    Comparative performance of endobronchial ultrasound-guided sampling techniques in patients with mediastinal lesions: a network meta-analysis.

    Thorax·2026
    Same journal

    Vitamin A and D impact on lung function: differential or common effects across the lifespan?

    Thorax·2026
    Same journal

    The impact of vitamins A and D on lung function and regulatory epigenetics in adult and childhood asthma.

    Thorax·2026
    Same journal

    Radiological factors associated with the recurrence of <i>Mycobacterium avium complex</i> pulmonary disease: a multicentre retrospective cohort study.

    Thorax·2026
    Same journal

    Daughter vesicles in primary diaphragmatic hydatid cyst.

    Thorax·2026
    See all related articles

    Area of Science:

    • Pulmonology
    • Nephrology
    • Pharmacology

    Background:

    • Cyclophosphamide is an alkylating agent used in chemotherapy and immunosuppression.
    • Interstitial lung disease (ILD) is a known rare adverse effect of cyclophosphamide therapy.
    • Previous reports primarily linked cyclophosphamide-induced ILD to lymphoma treatment.

    Observation:

    • A male patient undergoing treatment for glomerulonephritis developed interstitial pneumonitis and fibrosis.
    • The patient's respiratory insufficiency and lung pathology were temporally associated with cyclophosphamide administration.
    • Histopathological findings supported an etiological link between cyclophosphamide and the observed lung disease.

    Findings:

    • This case demonstrates cyclophosphamide-induced interstitial pneumonitis and fibrosis in a patient treated for glomerulonephritis.

    Related Experiment Videos

  • The findings suggest cyclophosphamide is a potential cause of lung disease in this context, extending beyond lymphoma patients.
  • A significant delay in clinical or radiological improvement (1+ months) may occur after discontinuing cyclophosphamide therapy.

    • Implications:

    • Clinicians should consider cyclophosphamide as a potential cause of ILD in patients with glomerulonephritis.
    • Awareness of this adverse effect is crucial for early diagnosis and management.
    • Delayed recovery underscores the importance of long-term monitoring for cyclophosphamide-induced lung injury.